ReviewEXCLI journal2020
Osteoporosis: Pathophysiology and therapeutic options.
Review in EXCLI journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 162 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
162 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The role of CD8Frontiers in immunology · 2026Pooled it
- The predictive value of immune inflammation indexes for the risk of fracture in patients with osteoporosis: a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Impact of anti-fracture medications on bone material and strength properties: a systematic review and meta-analysis.Frontiers in endocrinology · 2024Pooled it
- [Osteoporosis in pneumological diseases : Joint guideline of the Austrian Society for Bone and Mineral Research (ÖGKM) and the Austrian Society for Pneumology (ÖGP)].Wiener klinische Wochenschrift · 2021Guideline
- Can supplements with prebiotic fibres positively influence bone health in type 2 diabetes? Insights from a randomised controlled crossover trial.Archives of osteoporosis · 2025Trial
- The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trial.Archives of osteoporosis · 2023Trial
- Fragility fracture risk prediction using quantitative magnetic resonance and Vertebral Bone Quality scoring beyond density.World journal of methodology · 2026Review
- Camel Milk and Its Bioactive Components in Diseases Associated with Aging: A Narrative Review.Nutrients · 2026Review
- Preparation, characterization and evaluation of polysaccharides from Rosa roxburghii Tratt. fruit on ameliorating senior osteoporosis in rats induced by d-galactose and low calcium diet.Journal of the science of food and agriculture · 2026Article
- Heme Oxygenase-1 in Bone Remodeling: Molecular Mechanisms and Therapeutic Implications.Biomolecules · 2026Review
- Unprecedented rearranged triterpenoids with seven-membered rings fromRSC advances · 2026Article
- Plant-based macronutrients and micronutrients in combating osteoporosis: research insights and molecular pathways.RSC advances · 2026Review
- The NLRP12 Osteoimmune Checkpoint: Coordinating Inflammatory Signaling and Bone Remodeling.Biomedicines · 2026Review
- Changes in physical performance with aging in master athletes and in the general population: an update.European journal of translational myology · 2026Article
- Effect of the JAK Inhibitor Baricitinib on Cytokine Production and Bone Properties in a Mouse Model of Accelerated Aging.International journal of molecular sciences · 2026Article
- Cadmium causes osteoporosis by osteogenic differentiation inhibition via miR-155/SMAD5 pathway: evidence from in vivo and in vitro studies.Archives of toxicology · 2026Article
- Maternal Sleep Quality and Early-Life Epigenetic Programming of Bone-Related Genes in Neonatal Cord Blood: Findings from the PERSIAN Birth Cohort, Isfahan.Calcified tissue international · 2026Article
- A Standard Herbal Formula, CGAC, Attenuates Bone Loss by Normalizing Low-Bone Turnover Stagnation in an Orchiectomy-Induced Mouse Model.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Modulating Galectin-1 in human osteoblast-like cells alters mineralisation and influences the expression of genes associated with osteoblasts and osteocytes.Bioscience reports · 2026Article
- Mapping the quality of information on osteoporosis: a cross-sectional analysis of online health information.BMC musculoskeletal disorders · 2026Article
102 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a metabolic bone disease that, on a cellular level, results from osteoclastic bone resorption not compensated by osteoblastic bone formation. This causes bones to become weak and fragile, thus increasing the risk of fractures. Traditional pathophysiological concepts of osteoporosis focused on endocrine mechanisms such as estrogen or vitamin D deficiency as well as secondary hyperparathyroidism. However, research over the last decades provided exiting new insights into mechanisms contributing to the onset of osteoporosis, which go far beyond this. Selected mechanisms such as interactions between bone and the immune system, the gut microbiome, and cellular senescence are reviewed in this article. Furthermore, an overview on currently available osteoporosis medications including antiresorptive and bone forming drugs is provided and an outlook on potential future treatment options is given.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.